Skip to main content
. 2018 Apr;13(4):709–716. doi: 10.4103/1673-5374.230299

Figure 4.

Figure 4

Elevated lymphangiogenesis in dcLNs in APP/PS1 mice treated with rhVEGF-C.

(A) Elevated lymphangiogenesis in dcLNs of 9-month-old APP/PS1 mice treated with rhVEGF-C. Scale bar: 500 μm. (B) Relative area of the dcLNs of the two groups of mice. Lymphatic vessels were stained by Lyve-1 antibody (red), and the relative area of Lyve-1+ lymphatic vessels was measured by ImageJ. Data are presented as the mean ± SEM (n = 6; two-tailed Student's t-test). **P < 0.01, vs. control group. rhVEGF-C: Recombinant human vascular endothelial growth factor-C; dcLNs: deep cervical lymph nodes.